Intensity-modulated radiation therapy (IMRT) is an advanced and highly precise radiotherapy technique that employs computer-controlled linear accelerators to administer accurate radiation doses to malignant tumours or specific regions within the tumour. IMRT achieves this precision by modulating, or controlling, the intensity of the radiation beam across multiple small volumes. This approach allows the radiation dose to closely match the three-dimensional (3-D) shape of the tumour, enabling higher radiation doses to be targeted at the tumour while minimizing exposure to surrounding healthy tissues and critical structures.

Treatment planning involves the use of 3-D computed tomography (CT) or magnetic resonance imaging (MRI) scans of the patient, combined with computer-based dose calculations, to determine the optimal dose intensity pattern that conforms to the tumour’s shape. Typically, a combination of multiple intensity-modulated fields originating from different beam angles is employed to create a tailored radiation dose that maximizes tumour treatment while minimizing radiation exposure to neighbouring normal tissues.

Global Intensity-Modulated Radiotherapy Market was valued US$ 2.1 Bn in 2022 and is expected to reach ~US$ 2.8 Bn by 2032, growing at a CAGR of 5.8% during the forecast period 2023-2032.

The Intensity-Modulated Radiotherapy Market expansion is fuelled by several factors, including the increasing incidence of infections caused by drug-resistant pathogens, advancements in diagnostic technologies, and the rising concern over antimicrobial resistance, government initiatives aimed at tackling antimicrobial-resistant species, and the emergence of multi-drug resistance due to substance abuse. Conversely, the high expenses associated with antimicrobial resistance diagnostic systems and kits are constraining the market's growth.

Hospitals often uphold state-of-the-art facilities and technological capabilities necessary for effectively incorporating the Intensity-Modulated Radiation Therapy (IMRT) market. This ensures the ready availability of essential resources, and this crucial feature significantly contributes to the progress and strengthening of the Image-Guided Radiation Therapy (IGRT) market.

COVID -19 Impact on Intensity-Modulated Radiotherapy Market

The COVID-19 pandemic has had a significant impact on the Intensity-Modulated Radiotherapy (IMRT) market, both in terms of challenges and opportunities. The pandemic led to disruptions in cancer treatment schedules, including delays in radiation therapy sessions for many patients. This delay, especially for time-sensitive cases, may have had adverse effects on treatment outcomes. Healthcare resources, including radiation therapy equipment and personnel, were redirected to manage COVID-19 patients, leading to resource constraints in cancer treatment centers. Many cancer patients became apprehensive about visiting healthcare facilities due to the risk of exposure to COVID-19, leading to reduced patient volumes for radiation therapy. The global supply chain for medical equipment and radiation therapy machines experienced disruptions, impacting the availability and delivery of IMRT-related technology.

The pandemic accelerated the adoption of telemedicine and remote monitoring technologies, which could be leveraged for remote consultations, treatment planning, and follow-up care for cancer patients undergoing IMRT. The urgency of the pandemic may have spurred innovation in radiation therapy techniques, including IMRT, to make treatments more efficient, reduce the number of required sessions, and minimize patient exposure. The pandemic highlighted the vulnerability of individuals with underlying health conditions, including cancer patients. This may lead to increased awareness of cancer prevention and the importance of timely treatment, potentially driving demand for IMRT in the long run. Some governments and healthcare organizations may invest in upgrading cancer treatment infrastructure, including IMRT facilities, as part of their healthcare system strengthening efforts in response to the pandemic.

Factors Driving the Intensity-Modulated Radiotherapy Market

Drivers

Increase in non-invasive cancer treatments through radiation therapy

Progress in radiation therapy technology has ushered in a new era of precision and specificity in treatments. Approaches like intensity-modulated radiation therapy (IMRT), stereotactic body radiation therapy (SBRT), and proton therapy enable the delivery of radiation with exceptional accuracy, preserving healthy tissues and limiting adverse effects. In contrast to surgical procedures, non-invasive radiation therapy eliminates the need for surgical incisions or tissue removal. Consequently, it results in minimal scarring and shorter recovery periods, enabling patients to swiftly return to their usual routines.

The increase in non-invasive cancer treatments through radiation therapy can be attributed to advancements in technology and treatment techniques. Radiation therapy technology has evolved significantly over the years. Modern machines, such as linear accelerators, CyberKnife, and proton therapy systems, allow for highly targeted and precise delivery of radiation to cancerous tumors. These technologies enable non-invasive treatments by minimizing damage to surrounding healthy tissues. IGRT is an approach that combines real-time imaging with radiation therapy. It enables clinicians to monitor the tumor's position during treatment, ensuring that radiation is delivered accurately to the tumor while sparing nearby normal tissues. IGRT reduces the need for invasive procedures to reposition patients.

Non-invasive radiation therapy techniques are designed to minimize side effects and complications associated with cancer treatment. By sparing healthy tissues and organs from unnecessary radiation exposure, these approaches improve the patient's quality of life during and after treatment. In summary, the increase in non-invasive cancer treatments through radiation therapy is driven by advancements in technology and treatment techniques that allow for highly precise and targeted radiation delivery. These non-invasive approaches reduce the need for surgery and minimize side effects, making them more patient-friendly and effective in the treatment of various cancers.

Rising cancer patient population

The rising cancer patient population can be explained by several interconnected factors such as the global population continues to grow, there is a natural increase in the number of individuals who may develop cancer over their lifetimes. The sheer size of the population contributes to the overall increase in cancer cases. Cancer is more prevalent in older individuals, and many countries are experiencing demographic shifts toward older populations due to increased life expectancy. As people age, their risk of developing cancer also increases, leading to a higher number of cancer patients. Exposure to environmental carcinogens, such as tobacco smoke, air pollution, and certain chemicals, can contribute to the development of cancer. Changes in lifestyle, industrialization, and urbanization have increased exposure to these factors in many regions. According to the World Cancer Research Fund, there were an estimated 19.3 million new cancer cases worldwide in 2020, and this number is projected to increase to 27.5 million new cases by 2040. Cancer is one of the leading causes of death globally. In 2020, it accounted for approximately 9.6 million deaths, making it the second leading cause of death after cardiovascular diseases. The risk of cancer increases with age. As the global population continues to age, with more people living into their senior years, the incidence of cancer is expected to rise.

Numerous organizations and initiatives, such as the World Cancer Day, focus on raising awareness, promoting cancer prevention, and improving access to cancer care worldwide. Ongoing research and innovations in cancer diagnostics, treatments, and therapies aim to improve outcomes and reduce the burden of cancer. Many countries have implemented cancer control programs and national cancer plans to address the growing cancer patient population, enhance early detection, and improve treatment outcomes. These facts underscore the importance of global efforts to prevent, detect, and treat cancer, as well as the need for continued research and healthcare infrastructure to meet the rising demand for cancer care.

Challenge

Availability of alternative technology

Navigating the complex terrain of alternative technologies presents a formidable challenge for the IGRT (Image-Guided Radiation Therapy) market. This challenge is fuelled by the continuous progress in technology, the quest for improved treatment results, and the inherent competition among various cancer treatment methods. In the midst of this intricate landscape, the strategic ascent and expansion of Intensity-Modulated Radiation Therapy (IMRT) take on crucial significance. IMRT must adeptly align its distinctive features with the evolving demands of cancer care while concurrently competing with alternative technological choices.

Intensity-Modulated Radiotherapy Market Segmentation 

By Application

The global Intensity-Modulated Radiotherapy Market comprises major segments such as prostate, lung, breast, brain, gastrointestinal and other applications. IMRT empowers radiologists to execute intricate procedures through non-invasive means. The incorporation of Intensity-Modulated Radiation Therapy (IMRT) into the treatment of brain cancer is supported by its capability to navigate the complexities of brain anatomy, reduce treatment-related uncertainties, customize treatment plans, and harmonize with evolving therapeutic approaches. This combination of qualities substantially enhances the progression and prominence of IMRT within the realm of brain cancer treatment, thereby strengthening its strategic standing in the broader field of radiation therapy.

By Regions

By region, the market is divided into North America, Europe, APAC, and Others. Others is further divided into Middle East and South America.

During the forecast period, North America is anticipated to maintain its position as the dominant market in the field of intensity-modulated radiotherapy. In 2022, North America, encompassing the United States and Canada, commanded the largest share of the intensity-modulated radiotherapy market. This can be attributed to the region's robust healthcare infrastructure and its access to state-of-the-art medical technologies, making it a conducive environment for the adoption of advanced treatment approaches such as Intensity-Modulated Radiation Therapy (IMRT).

The aging population demographics observed in Asia-Pacific (APAC) countries underscore the importance of effective cancer treatment methods that minimize treatment-related side effects. This alignment with the precision-oriented characteristics of the Intensity-Modulated Radiation Therapy market validates its crucial role in improving the overall healthcare landscape.

The incorporation of multilingual patient care services within APAC hospitals, combined with the availability of advanced treatments like Intensity-Modulated Radiation Therapy, adds a unique appeal to the region, especially among a diverse patient population. This combination of linguistic inclusivity and cutting-edge medical interventions significantly enhances the region's attractiveness as a preferred healthcare destination, strengthening its competitive position in the healthcare market and concurrently boosting the prominence of IMRT.

Competitive Landscape of Intensity-Modulated Radiotherapy Market

The competitive landscape of the Intensity-Modulated Radiotherapy (IMRT) market is characterized by several key players and dynamic factors that shape the industry's dynamics. Established companies like Varian Medical Systems (acquired by Siemens Healthineers), Elekta AB, and Accuray Incorporated have historically been leaders in the IMRT market. They offer a wide range of radiation therapy equipment and solutions and have a global presence. The IMRT market is highly driven by technological advancements. Companies like ViewRay, Inc. have introduced innovative solutions, such as MRI-guided radiation therapy, which offer real-time imaging during treatment. Many companies invest significantly in research and development to create cutting-edge IMRT technologies. This includes developing more precise treatment planning software, advanced linear accelerators, and treatment delivery systems. Partnerships and collaborations between industry players and healthcare institutions are common. These collaborations aim to advance research, develop new treatment techniques, and improve the accessibility of IMRT.

In addition to global leaders, there are regional players and manufacturers who provide IMRT equipment and solutions. These companies often cater to specific markets or regions. Companies are expanding their presence in emerging markets, particularly in Asia-Pacific, to tap into the growing demand for advanced cancer treatment options. These efforts involve establishing distribution networks, partnerships, and local manufacturing facilities. Leading companies often have diversified product portfolios that encompass not only IMRT equipment but also other radiation therapy solutions, including Image-Guided Radiation Therapy (IGRT) and Stereotactic Body Radiation Therapy (SBRT).

Recent Developments in the Intensity-Modulated Radiotherapy Market

• In July 2022, Boehringer Ingelheim, bioMérieux, and Evotec SE jointly announced the establishment of a venture to develop actionable diagnostics and the next generation of antibiotics, with the objective of reducing the burden of antimicrobial resistance. Within this joint venture, bioMerieux will focus on developing testing solutions for antibiotic resistance, allocating a significant portion, 80%, of the total investment toward the fight against AMR.

• In April 2022, bioMerieux unveiled its acquisition agreement with Specific Diagnostics. This strategic move has bolstered its standing in the worldwide market for antimicrobial resistance diagnostics.

• In January 2022, BD unveiled a partnership with Pfizer Inc. and a global charitable foundation, Wellcome, with the goal of advancing knowledge in diagnostics and testing solutions to enhance antimicrobial stewardship practices worldwide. This collaborative effort aims to assess existing testing practices, gaining insights into both the shortcomings and advantages of antimicrobial resistance diagnostic procedures.

• In September 2021, MeMed disclosed that its MeMed BV diagnostic test received 510(k) clearance from the U.S. FDA. This test is designed for discerning between bacterial and viral infections in point-of-care environments.
• In October 2021, Hologic, Inc introduced the fully automated Novodiag molecular diagnostic solution by Mobidiag Oy in Europe, offering on-demand testing for antimicrobial resistance and infectious diseases. The Novodiag system combines microarray and real-time PCR capabilities, enabling the identification of multiple pathogens from a single sample.
• In October 2021, OpGen, Inc. disclosed that it had received 510(k) clearance from the U.S. FDA to market the Acuitas AMR Gene Panel. This panel is capable of testing 28 genetic antimicrobial resistance markers across various pathogens and will assist healthcare professionals in managing patients with antibiotic-resistant bacterial infections.

Global Intensity-Modulated Radiotherapy Market Segmentation

Intensity-Modulated Radiotherapy by Radiation Type: Market Size & Forecast 2023-2030

• Photon Beam
• Electron Beam
• Proton and Carbon-Ion Radiation

Intensity-Modulated Radiotherapy by Application: Market Size & Forecast 2023-2030

• Prostate
• Lung
• Breast
• Head and Neck
• Gynecological
• Other

Intensity-Modulated Radiotherapy by End Users: Market Size & Forecast 2023-2030

• Hospitals
• Independent Radiotherapy Centers

Intensity-Modulated Radiotherapy by Geography: Market Size & Forecast 2023-2030

• North America (USA, Canada, Mexico)
• Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
• Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
• South America (Brazil, Argentina, Columbia, Rest of South America)
• Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Major Players:

• Varian Medical Systems, Inc.
• Elekta AB
• Accuray Incorporated
• Siemens Healthineers AG
• ViewRay, Inc.
• IBA Worldwide
• Mevion Medical Systems, Inc.
• ProTom International
• IntraOp Medical Corporation
• Sumitomo Heavy Industries, Ltd.
• Shinva Medical Instrument Co., Ltd.
• Hitachi, Ltd.
• Mitsubishi Electric Corporation
• C-RAD AB
• Brainlab AG
• Nordion (Canada) Inc.
• Nanobiotix SA
• RaySearch Laboratories AB
• RefleXion Medical
• Sentinel Oncology Ltd.
• Zap Surgical Systems, Inc.
• Accuray Japan Inc.
• Elekta Limited
• Advanced Oncotherapy plc
• CIRCULOGENE Theranostics, LLC